Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Sep 29, 2022 8:03am
142 Views
Post# 34994238

RE:RE:total ballpark deal value

RE:RE:total ballpark deal value Good response and can certainly appreciate that perspective.. I guess some people are looking for a take your money and run scenario and are unwilling to wait for the sales to accrue.

This is like a forced pension plan to keep the company and science development going for the next two decades. 

This other way to look at it is that its like buying a revenue ticket on the 17 yr Abbvie train with payments for every kilometer travelled. The question one has to ask is if Abbvie will follow through on the sales. That part I not so worried about as they are a grade A company and we get a % of sales this time around.

At this point, if I was to have the choice between 10-15M upfront or a long term royalty I think I would take the long game with the decent royalties simply because Sirona would burn through that  upfront and not sure where things would end up in a year or two. Then we are back to repeating interim financing.

As soon as they have a few quarters of decent revenue the full value on this deal may be reflected then I suppose. But then again that still wouldn't explain why we are trading lower than when the deal was announced.

I am going to call it now and say whatever one can pick up cheap today and maybe tomorrow (we will see what financials bring) could very well be that last time there is a value deal on shares from this point forward as investors sort through their disappointment with Howard.

Happy to be wrong on that, but very likely going to take full advantage of the situation here.










<< Previous
Bullboard Posts
Next >>